From: Focused ultrasound-mediated drug delivery to pancreatic cancer in a mouse model
N | Treatment group | MRgHIFU parameters | Time between injection and MRgFUS (h) | Life span (weeks)a | |||
---|---|---|---|---|---|---|---|
Trajectory | Acoustic pressure (MPa) | Duty cycle (%), pulse length | Total sonication time (s) | ||||
7 | Negative control (no injection, no MRgFUS) | N/A | N/A | N/A | N/A | N/A | 3.5 ± 0.5 |
7 | PTX-nanodroplets + No MRgFUS | 7.0 ± 0.8 | |||||
1 | No injection + MRgFUS | Spiral | 3.4 | 100 | 240 | 4.8 ± 2.3 | |
1 | 4.2 | 60 | |||||
4 | Grid | 3.4 | 325 ± 29 | ||||
4 | 4.2 | 300 | |||||
3 | Empty nanodroplets + No MRgFUS | N/A | N/A | N/A | N/A | 6 to 8 | 3.5 ± 0.5 |
1 | Empty nanodroplets + MRgFUS | Spiral | 3.4 | 100 | 60 | 6 to 8 | 3.5 ± 2.1b |
2 | 4.2 | 60 | |||||
1 | 4.8 | 240 | |||||
4 | Grid | 3.4 | 313 ± 25 | ||||
4 | PTX-nanodroplets + MRgFUS | Grid | 3.4 | 100 | 300 | 1 to 2 | 7.0 ± 1.0 |
1 | 2.4 | ||||||
4 | Spiral | 3.4 | 100 | 153 ± 54 | 6 to 8 | 10.3 ± 1.6c | |
4 | 2.4 | 100 | 130 ± 50 | ||||
1 | 4.2 | 100 | 60 | ||||
1 | 4.8 | 100 | 60 | ||||
5 | Grid | 3.4 | 100 | 300 | |||
2 | 4.8 | 100 | 300 | ||||
2 | 4.2 | 100 | 300 | ||||
1 | Grid | 3.4 | 50 (50 ms) | 300 | 6.0 ± 1.4 | ||
1 | Grid | 4.2 | 50 (50 ms) | 300 | |||
1 | Spiral | 3.4 | 50 (100 ms) | 300 | |||
1 | Spiral | 4.8 | 50 (50 ms) | 300 |